{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-089108","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.197112+00:00","generated_at":"2026-05-30T12:26:42.310299+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CERo submits complete response letter to FDA clinical hold for CERO-1236; clinic entry now expected early 2025","bullets":["Submitted complete response to FDA clinical hold on CERO-1236; 30-day review cycle expected.","Adjusted clinical trial entry from 2024 to early 2025 based on FDA timeline.","Cash balance of $3.2M as of Sept 30, 2024, sufficient for near-term strategy execution.","Al Kucharchuk appointed CFO; Kristen Pierce promoted to Chief Development Officer.","Board of Directors changes made to enhance business plan execution."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-089108","json":"https://secwatch.observer/filing/0001213900-24-089108.json","markdown":"https://secwatch.observer/filing/0001213900-24-089108.md","text":"https://secwatch.observer/filing/0001213900-24-089108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024089108/0001213900-24-089108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024089108/ea021808801-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:26:42.310299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}